Cardiff Oncology, Inc. (CRDF)

Cardiff Oncology Statistics

Total Valuation

CRDF has a market cap or net worth of $174.10 million. The enterprise value is $90.72 million.

Market Cap	174.10M
Enterprise Value	90.72M

Important Dates

The next estimated earnings date is Tuesday, November 12, 2024, after market close.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

CRDF has 46.55 million shares outstanding. The number of shares has increased by 0.93% in one year.

Shares Outstanding	46.55M
Shares Change (YoY)	+0.93%
Shares Change (QoQ)	+0.33%
Owned by Insiders (%)	2.07%
Owned by Institutions (%)	26.55%
Float	43.17M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	215.51
Forward PS	661.09
PB Ratio	2.79
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	136.41
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.97, with a Debt / Equity ratio of 0.04.

Current Ratio	4.97
Quick Ratio	4.85
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -58.80% and return on invested capital (ROIC) is -38.95%.

Return on Equity (ROE)	-58.80%
Return on Assets (ROA)	-34.12%
Return on Capital (ROIC)	-38.95%
Revenue Per Employee	$20,781
Profits Per Employee	-$1.28M
Employee Count	32
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +236.94% in the last 52 weeks. The beta is 1.93, so CRDF's price volatility has been higher than the market average.

Beta (5Y)	1.93
52-Week Price Change	+236.94%
50-Day Moving Average	2.63
200-Day Moving Average	3.00
Relative Strength Index (RSI)	79.84
Average Volume (20 Days)	774,063

Short Selling Information

The latest short interest is 7.32 million, so 15.71% of the outstanding shares have been sold short.

Short Interest	7.32M
Short Previous Month	6.83M
Short % of Shares Out	15.71%
Short % of Float	16.94%
Short Ratio (days to cover)	13.38

Income Statement

In the last 12 months, CRDF had revenue of $665,000 and -$40.88 million in losses. Loss per share was -$0.92.

Revenue	665,000
Gross Profit	-32.62M
Operating Income	-44.63M
Pretax Income	-40.86M
Net Income	-40.88M
EBITDA	-44.21M
EBIT	-44.63M
Loss Per Share	-$0.92

Balance Sheet

The company has $60.32 million in cash and $1.84 million in debt, giving a net cash position of $58.48 million or $1.26 per share.

Cash & Cash Equivalents	60.32M
Total Debt	1.84M
Net Cash	58.48M
Net Cash Per Share	$1.26
Equity (Book Value)	52.39M
Book Value Per Share	1.15
Working Capital	49.72M

Cash Flow

In the last 12 months, operating cash flow was -$32.07 million and capital expenditures -$403,000, giving a free cash flow of -$32.47 million.

Operating Cash Flow	-32.07M
Capital Expenditures	-403,000
Free Cash Flow	-32.47M
FCF Per Share	-$0.70

Margins

Gross Margin	n/a
Operating Margin	-6,711.28%
Pretax Margin	-6,143.91%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-4,882.56%

Dividends & Yields

CRDF does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.93%
Shareholder Yield	-0.93%
Earnings Yield	-27.40%
FCF Yield	-21.76%

Analyst Forecast

The average price target for CRDF is $9.67, which is 158.56% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$9.67
Price Target Difference	158.56%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	-26.88%
EPS Growth Forecast (5Y)	19.80%

Stock Splits

The last stock split was on February 20, 2019. It was a reverse split with a ratio of 0.1666666:1.

Last Split Date	Feb 20, 2019
Split Type	Reverse
Split Ratio	0.1666666:1

Scores

CRDF has an Altman Z-Score of -4.39 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.39
Piotroski F-Score	3